Jpmorgan Chase & CO Aeglea Bio Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.35 - $1.54 $902 - $3,970	-2,578 Reduced 70.71%	1,068 $0
Q3 2022 Nov 14, 2022	BUY	$0.38 - $0.81 $503 - $1,072	1,324 Added 57.02%	3,646 $2,000
Q2 2022 Aug 11, 2022	SELL	$0.5 - $2.66 $11,300 - $60,118	-22,601 Reduced 90.68%	2,322 $1,000
Q1 2022 May 11, 2022	BUY	$1.87 - $4.77 $7,564 - $19,294	4,045 Added 19.37%	24,923 $58,000
Q4 2021 Feb 10, 2022	BUY	$3.5 - $8.42 $5,918 - $14,238	1,691 Added 8.81%	20,878 $99,000
Q3 2021 Nov 12, 2021	BUY	$6.03 - $7.95 $115,697 - $152,536	19,187 New	19,187 $152,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.